背景:帕金森病(PD)是第二常见的神经退行性疾病。早期检测对于治疗和减缓疾病进展至关重要。
目的:来自定量磁化率图(QSM)的平均磁化率(MS)和来自扩散峰度成像(DKI)的平均峰度(MK)的同时改变可以作为基底神经节核中早期PD(ESPD)的可靠神经成像生物标志物,包括黑质(SN),壳核(PUT),苍白球(GP),和尾状核(CN)。
方法:系统评价和荟萃分析。
方法:从四项研究中纳入了111名诊断为ESPD的患者和81名健康对照(HC),这些研究在两个受试者组中同时使用了QSM和DKI。
■用于QSM的三维多回波梯度回波序列和用于3特斯拉的DKI的自旋回波平面成像序列。
结果:使用PRISMA指南的系统评价和荟萃分析搜索了PubMed,WebofScience,还有Scopus.
方法:随机效应模型,标准化平均差异(SMD)比较ESPD患者和HCs之间的MS和MK,用于异质性的I2统计量,纽卡斯尔-渥太华量表(NOS)的偏见风险,和Egger对出版偏见的检验。P值<0.05被认为是显著的。
结果:MS值在SN中明显更高(SMD0.72,95%CI0.31至1.12),PUT(SMD0.68,95%CI0.29至1.07),与HCs相比,ESPD患者和GP(SMD0.53,95%CI0.19至0.87)。CN没有显示MS值的显著差异(P=0.15)。MK值仅在SN中明显更高(SMD=0.72,95%CI0.16至1.27)。MK值在PUT中没有显着差异(P=1.00),GP(P=0.97),和CN(P=0.59)。研究质量较高(NOS7-8),无发表偏倚(P=0.967)。
结论:同时使用MS和MK可作为早期神经影像学生物标志物用于ESPD检测及其与HC的区别,在SN中观察到显著差异。
方法:2技术效果:阶段2。
BACKGROUND: Parkinson\'s disease (PD) is the second most common neurodegenerative disorder. Early detection is crucial for treatment and slowing disease progression.
OBJECTIVE: Simultaneous alterations in mean susceptibility (MS) from quantitative susceptibility mapping (QSM) and mean kurtosis (MK) from diffusion kurtosis imaging (DKI) can serve as reliable neuroimaging biomarkers for early-stage PD (ESPD) in the basal ganglia nuclei, including the substantia nigra (SN), putamen (PUT), globus pallidus (GP), and caudate nucleus (CN).
METHODS: Systematic review and meta-analysis.
METHODS: One hundred eleven patients diagnosed with ESPD and 81 healthy controls (HCs) were included from four studies that utilized both QSM and DKI in both subject groups.
UNASSIGNED: Three-dimensional multi-echo gradient echo sequence for QSM and spin echo planar imaging sequence for DKI at 3 Tesla.
RESULTS: A systematic review and meta-analysis using PRISMA guidelines searched PubMed, Web of Science, and Scopus.
METHODS: Random-effects model, standardized mean difference (SMD) to compare MS and MK between ESPD patients and HCs, I2 statistic for heterogeneity, Newcastle-Ottawa Scale (NOS) for risk of bias, and Egger\'s test for publication bias. A P-value <0.05 was considered significant.
RESULTS: MS values were significantly higher in SN (SMD 0.72, 95% CI 0.31 to 1.12), PUT (SMD 0.68, 95% CI 0.29 to 1.07), and GP (SMD 0.53, 95% CI 0.19 to 0.87) in ESPD patients compared to HCs. CN did not show a significant difference in MS values (P = 0.15). MK values were significantly higher only in SN (SMD = 0.72, 95% CI 0.16 to 1.27). MK values were not significantly different in PUT (P = 1.00), GP (P = 0.97), and CN (P = 0.59). Studies had high quality (NOS 7-8) and no publication bias (P = 0.967).
CONCLUSIONS: Simultaneous use of MS and MK may be useful as an early neuroimaging biomarker for ESPD detection and its differentiation from HCs, with significant differences observed in the SN.
METHODS: 2 TECHNICAL EFFICACY: Stage 2.